Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
2.
Bioorg Med Chem Lett ; 27(20): 4730-4734, 2017 10 15.
Artigo em Inglês | MEDLINE | ID: mdl-28947155
3.
J Chem Inf Model ; 54(2): 377-86, 2014 Feb 24.
Artigo em Inglês | MEDLINE | ID: mdl-24437550

RESUMO

A phenotypic screen (PS) is used to identify compounds causing a desired phenotype in a complex biological system where mechanisms and targets are largely unknown. Deconvoluting the mechanism of action of actives and identification of relevant targets and pathways remains a formidable challenge. Current methods fail to use the rich information available regarding compounds and their targets in a systematic way for this deconvolution. We have developed an enrichment analysis algorithm to identify targets associated with the desired phenotype in a rigorous data-driven manner using actives and hundreds of thousands of inactives in a PS, as well as results of thousands of available legacy target-based screens in an institution. Our method quantifies association between the PS and targets while reducing sampling bias, which leads to identification of novel targets, additional chemical matter, and appropriate assays. Its use is illustrated using two examples from our laboratories: TRAIL and DNA fragmentation. Enrichment analysis of these PSs is discussed using both biological pathway analysis and known cell biology to demonstrate the value of our method. We believe this enrichment analysis method is an indispensable tool for the analysis of PSs.


Assuntos
Avaliação Pré-Clínica de Medicamentos/métodos , Fenótipo , Algoritmos , Fragmentação do DNA/efeitos dos fármacos , Ensaios de Triagem em Larga Escala , Ligante Indutor de Apoptose Relacionado a TNF/metabolismo
4.
Bioorg Med Chem Lett ; 23(5): 1498-501, 2013 Mar 01.
Artigo em Inglês | MEDLINE | ID: mdl-23333208

RESUMO

A series of tetrahydroisoquinolines were designed, synthesized and evaluated as the first non-natural product type of compounds with dual D(1) receptor (D(1)R) agonism and D(2) receptor (D(2)R) antagonism properties for treatment of schizophrenia. The initial SAR of the series was explored. The lead in the series, 3g, exhibited high affinity and good potency. Compound 3g displayed 95% of D(1)R occupancy (10 mg/kg, sc) and 75% of D(2)R occupancy (10 mg/kg, sc) in the striatum of male CD-1 mice. The series exhibited unique pharmacology and merit as tool compounds for target validation and future optimizations.


Assuntos
Antagonistas dos Receptores de Dopamina D2 , Receptores de Dopamina D1/agonistas , Esquizofrenia/tratamento farmacológico , Tetra-Hidroisoquinolinas/química , Tetra-Hidroisoquinolinas/farmacologia , Animais , Desenho de Fármacos , Masculino , Camundongos , Receptores de Dopamina D1/metabolismo , Receptores de Dopamina D2/metabolismo , Esquizofrenia/patologia , Relação Estrutura-Atividade , Tetra-Hidroisoquinolinas/síntese química
5.
Org Biomol Chem ; 2(3): 301-6, 2004 Feb 07.
Artigo em Inglês | MEDLINE | ID: mdl-14747857

RESUMO

A new generation of PNP compounds bearing different diarylphosphine groups were prepared and used as ligands in palladium-catalysed Suzuki cross-coupling reactions. Rates of oxidative addition of iodobenzene to (PNP)Pd[0] complexes were measured using UV spectroscopy. Synergistic effects between the N- and P- substituents were identified and correlated in redox and catalytic chemistry.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...